Search

Displaying results 1611 - 1620 of 7604 in total
  1. Drug

    Thymidine

    go.drugbank.com/drugs/DB04485
    ApprovedInvestigational

    Thymidine is a naturally occurring deoxyribonucleoside that is a crucial component of the DNA salvage pathway and a building block for DNA synthesis. … [A274683] While it lacks significant anti-tumor activity on its own,[A274688] it has been extensively investigated for nearly a decade as a biochemical modulator to enhance the efficacy and reduce the

  2. Drug

    Vutrisiran

    go.drugbank.com/drugs/DB16699
    ApprovedInvestigational

    [A249025,L42065] This delivery platform gives vutrisiran high potency and metabolic stability, and allows for subcutaneous injections to take place once every three months. … [L42085] Another siRNA indicated for the treatment of polyneuropathy associated with hereditary ATTR is [patisiran].[A249010] Vutrisiran was approved by the FDA in June 2022.

  3. Drug

    Methylchloroisothiazolinone

    go.drugbank.com/drugs/DB14197
    Approved

    The American Contact Dermatitis Society named Methylchloroisothiazolinone the Contact Allergen of the Year for 2013. … It is also a known dermatological sensitizer and allergen; some of its side effects include flaky or scaly skin, breakouts, redness or itchiness, and moderate to severe swelling in the eye area.

    Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    Selpercatinib

    go.drugbank.com/drugs/DB15685
    ApprovedInvestigational

    Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes. … Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.

  5. Drug

    Difelikefalin

    go.drugbank.com/drugs/DB11938
    ApprovedInvestigational

    [L36420,L36395] Difelikefalin was later approved by the EMA in April 2022 for the same indication.[L41665] … [A237620] Options for therapy are limited - with no FDA-approved treatments, off-label [gabapentin] was the most evidence-based and widely available treatment.

  6. Drug

    Nortriptyline

    go.drugbank.com/drugs/DB00540
    ApprovedInvestigational

    [L11878] It is used in the treatment of major depression and is also used off-label for chronic pain and other conditions.[L11881]

    Categories: Antidepressive Agents Indicated for Depression
  7. Drug

    Tavaborole

    go.drugbank.com/drugs/DB09041
    Approved

    Tavaborole functions by inhibiting Leucyl-tRNA synthetase, or LeuRS, an essential fungal enzyme required for protein synthesis and for the catalysis of ATP-dependent ligation of L-leucine to tRNA(Leu). … Tavaborale is a novel, boron-based topical antifungal medication for the treatment of onychomycosis, a fungal infection of the nail and nail bed due to *Trichophyton rubrum* or *Trichophyton mentagrophytes

    Categories: Antifungals for Topical Use, Antifungals for Dermatological Use
  8. Drug

    Ombitasvir

    go.drugbank.com/drugs/DB09296
    ApprovedInvestigational

    First approved in January 2015, Holkira Pak is indicated for the treatment of HCV genotype 1b with or without cirrhosis, and when combined with [DB00811] for the treatment of HCV genotype 1a with or without … First approved in December 2014, Viekira Pak is indicated for the treatment of HCV genotype 1b without cirrhosis or with compensated cirrhosis, and when combined with Ribavirin for the treatment of HCV

    Categories: Antivirals for Systemic Use, Treatments for Hepatitis C
  9. Drug

    Elamipretide

    go.drugbank.com/drugs/DB11981
    ApprovedInvestigational

    Elamipretide is a mitochondrial cardiolipin binder being investigated for diseases involving mitochondrial dysfunction. … Food and Drug Administration (FDA) granted accelerated approval for FORZINITY™ (elamipretide) to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg.

  10. Drug

    Doxercalciferol

    go.drugbank.com/drugs/DB06410
    ApprovedInvestigational

    Doxercalciferol is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis, as well as for the treatment of secondary hyperparathyroidism in patients … Doxercalciferol is a synthetic vitamin D2 analog that undergoes metabolic activation in vivo to form 1α,25-dihydroxyvitamin D2 (1α,25-(OH)2D2), a naturally occurring, biologically active form of vitamin